HOOKIPA Pharma
Manufacturing · New York, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
350 5th Ave Ste 7240 Fl 72, New York, Ne...Phone Number
(431) 890-6360Website
www.hookipapharma.comRevenue
$9.4 MillionStock Symbol
HOOKIndustry
About HOOKIPA Pharma
HOOKIPA Pharma Inc. (NASDAQ: HOOK) was founded in 2011, and is headquartered in New York City. They are a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that reprograms the body's immune system. HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens.Explore more
HOOKIPA Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to HOOKIPA Pharma
Compare insights from companies similar to HOOKIPA Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
HOOKIPA Pharma
$9.4M
51-200
Public
$21.3M
2011
TC
Terry CoelhoExecutive Vice President & Chief Financial Officer
HOOKIPA Pharma Tech Stack
A closer look at the technologies used by HOOKIPA Pharma
See more technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding HOOKIPA Pharma
Sign Up For FreeTo access detailed company insights
HOOKIPA Pharma Inc. (NASDAQ: HOOK) was founded in 2011, and is headquartered in New York City. They are a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that reprograms the body's immune system. HOOKIPA is building a proprietary immuno-oncology pipeline by targeting... Read More
